However, long-term tumor-suppressing effects of ICIs have been observed in other indications such as melanoma [35]; therefore, we performed a post-therapeutic progression study to assess potential differences between the longer-term effects of REG and REG + aPD1. The gene discussed is REG1A; the disease is neoplasm.